C-X-C 基序趋化因子配体 (CXCL8)，也称为白细胞介素-8，是一种典型的 CXC 家族趋化因子，带有谷氨酸-亮氨酸-精氨酸 (ELR) 基序，在人类一系列癌症的发生和进展中发挥着关键作用。先前的许多研究都集中在探索CXCL8基因多态性与癌症风险之间的关系。然而，其中许多报告的统计能力有限，在许多情况下会产生不明确或相互矛盾的结果。因此，使用关键字“IL”在 PubMed、万方、Scopus 和 Web of Science 数据库中搜索了截至 2023 年 7 月 20 日发表的文章-8”或“白介素-8”或“CXCL8”、“多态性”和“癌症”或“肿瘤”。使用比值比 (OR) 和 95% 置信区间 (CI) 来检查关联性。通过 TaqMan 检测评估了 CXCL8 781 多态性基因型。为了更好地了解这些多态性与疾病风险之间的关联，我们进行了大约 29 篇相关出版物。 CXCL8 -353A/T 多态性与总体癌症风险增加相关[A 与 T，比值比 (OR) = 1.255，95% 置信区间 (CI) (1.079-1.459)，异质性 = 0.449，P = 0.003] 。 CXCL8 781 T/C 等位基因同样与白种人中较高的癌症风险相关[TT vs. TC  CC，OR = 1.320，95%CI (1.046-1.666)，Pheterogenity = 0.375，P = 0.019]。此外，携带CXCL8 781 TT  TC基因型的口腔癌患者与CC基因型相比，血清CXCL8水平显着升高（P < 0.01），并且与基因型匹配的正常对照相比也表现出相似的趋势（P < 0.01） 。最后，应注意一些局限性，例如纳入研究中可能存在的发表偏倚或异质性。目前的研究表明，CXCL8 -353 和 781 多态性可能与较高的癌症风险相关，这可能会影响癌症预防，通过 CXCL8 的不同表达进行诊断或治疗。同时，781 多态性可能进一步提供作为生物标志物的价值，有助于口腔癌的早期识别和预后评估。© 2024。作者。

C-X-C motif chemokine ligand (CXCL8), also known as interleukin-8, is a prototypical CXC family chemokine bearing a glutamic acid-leucine-arginine (ELR) motif that plays key roles in the onset and progression of a range of cancers in humans. Many prior studies have focused on exploring the relationship between CXCL8 gene polymorphisms and the risk of cancer. However, the statistical power of many of these reports was limited, yielding ambiguous or conflicting results in many cases.Accordingly, the PubMed, Wanfang, Scopus and Web of Science databases were searched for articles published until July 20, 2023 using the keywords 'IL-8' or 'interleukin-8' or 'CXCL8', 'polymorphism' and 'cancer' or 'tumor'. Odds ratios (ORs) and 95% confidence intervals (CIs) were utilized to examine the association. The CXCL8 +781 polymorphism genotypes were assessed with a TaqMan assay.About 29 related publications was conducted in an effort to better understand the association between these polymorphisms and disease risk. The CXCL8 -353A/T polymorphism was associated with an increased overall cancer risk [A vs. T, odds ratio (OR) = 1.255, 95% confidence interval (CI) (1.079-1.459), Pheterogeneity = 0.449, P = 0.003]. The CXCL8 +781 T/C allele was similarly associated with a higher risk of cancer among Caucasians [TT vs. TC + CC, OR = 1.320, 95%CI (1.046-1.666), Pheterogeneity = 0.375, P = 0.019]. Furthermore, oral cancer patients carrying the CXCL8 +781 TT + TC genotypes exhibited pronounced increases in serum levels of CXCL8 as compared to the CC genotype (P < 0.01), and also shown similar trend as compared to genotype-matched normal controls (P < 0.01). Finally, several limitations, such as the potential for publication bias or heterogeneity among the included studies should be paid attention.Current study suggested that the CXCL8 -353 and +781 polymorphisms may be associated with a greater risk of cancer, which might impact cancer prevention, diagnosis, or treatment through the different expression of CXCL8. At the same time, the +781 polymorphism may further offer value as a biomarker that can aid in the early identification and prognostic evaluation of oral cancer.© 2024. The Author(s).